Stockwatch: Pandemic Cuts Deep Into Early Commercial Biotech
Traditional Field Force Dynamics Are Challenged Under COVID-19
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.
Pfizer’s results may have heralded a third-quarter stabilization of pandemic-related effects had the costs and expectations for its vaccine not hijacked sentiment.